Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
 escalating single and multiple intravenous (IV) infusions and subcutaneous (SC) injections of
 PF 06823859 in healthy subjects.
Inclusion Criteria:

 1. Healthy female subjects of non childbearing potential and male subjects who, at the
 time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is
 defined as no clinically relevant abnormalities identified by a detailed medical
 history, full physical examination, including blood pressure and pulse rate
 measurement, 12 lead ECG or clinical laboratory tests.

 2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

 Exclusion Criteria:

 1. History of active or latent tuberculosis (TB) regardless of treatment; positive
 Quantiferon - TB test.

 2. Subjects with a history of autoimmune disorders.

 3. Subjects with a history of or positive results for any of the following serological
 tests: Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), anti
 Hepatitis C antibody (HCVAb) or human immunodeficiency virus (HIV).